Royalty Report: Drugs, Vaccine, Cancer – Collection: 230762

License Grant

The Japanese Licensor grants a non-exclusive, worldwide, except for Japan, perpetual license, with the right to grant sublicenses, under the Licensors Patents, solely to research, develop, make, have made, use, have used, sell, offer for sale, have sold, keep and import Licensee Products in the Licensee Licensed Field.

This agreement also includes a non-exclusive and exclusive grant back from Licensee to Licensor.

License Property

L523S Antigen shall mean that Antigen containing certain nucleic and amino acid sequences.
L523S Vaccine shall mean a Vaccine which contains all or a portion of the L523S Antigen.

Licensor Patents shall mean all patents and patent applications; that cover patentable inventions or discoveries made by Licensor solely or together with a Third Party in the course of the Initial Agreement Activities, or, that cover patentable inventions or discoveries that generically or specifically claim all or any part of any L523S, Vaccine, a process for manufacturing any L523S: Vaccine, intermediates used in such process or a use of any L523S Vaccine, and which are now or become owned and/or controlled by Licensor and/or under which Licensor otherwise has, now or in the future, the right to grant licenses. Included within the definition of Licensor Patents are any continuations, continuations-in-part, divisions, patents of addition, reissues, renewals, extensions, improvement patents and/or foreign counterparts thereof.   In no event shall Licensor Patents be deemed to include the Licensee Patents.  

Licensee Products shall mean all Licensee Antibody Products and Licensee Vaccine Product.

L523S is an RNA-binding protein as a potential therapeutic target for lung cancer.

Field of Use

Licensees Licensed Field shall mean solid tumors in humans.

License Grant

Licensor grants to the Japanese Licensee an option to have Licensor supply adjuvants owned or solely developed by Licensor to Licensee.

This agreement also includes a non-exclusive grant back from Licensee to Licensor.

License Property

This license relates to the L523S vaccine.  L523S is a RNA-binding protein as a potential therapeutic target for lung cancer.

Licensor Adjuvant Know-How shall mean any technical information, materials or know-how exclusively related to any adjuvant owned or controlled by Licensor, including without limitation the protein Leishmania Elongation Initiation Factor, known as LeIF, MPL, or any synthetic adjuvant.

Antigen(s) shall mean the antigens and/or protein and/or other physical form based on such antigens, such as peptides and/or nucleic acids(s) (DNA, RNA) delivered in any form, including recombinant vectors, to the extent such antigens are covered by one or more Valid Claim(s) of any of the Licensor Patents.

Field of Use

Licensees Licensed Field shall mean solid tumors in humans; provided, however, that the Licensed Field shall specifically exclude the use of any L523S Vaccine as an ex vivo adoptive immunotherapeutic and prophylactic for any and all cancers, including the use of dendritic cells as vaccines, any L523S Vaccine as a diagnostic and Antigens as targets for small molecules, therapeutics and/or prophylactics.

License Grant

Licensor grants to Licensee of the United Kingdom a non-exclusive license under Technology to develop, have developed, make, have made, use, have used, sell, offer for sale, have sold, keep and/or import in the Territory and in the Field any Products and/or Combinations in any formulation, composition or delivery systems which contain any of the following two Licensed Antigens:
• Any and all ANTIGENS expressed in Prostate Cancer
• Any and all ANTIGENS expressed in Breast Cancer.

In further consideration of the obligations assumed by Licensee and subject to the terms and conditions of this Agreement, as of May 22, 2002 Licensee grants a non-exclusive license under Technology to develop, have developed, make, have made, use, have used, sell, offer for sale, have sold, keep and/or import in the Territory and in the Field any Products and/or Combinations in any formulation, composition or delivery systems which contain the following Licensed Antigens:
• Any and all Antigens expressed in Lung Cancer

License Property

The Product shall mean any and all pharmaceutical compositions for Prophylactic Immunization and/or Therapeutic Immunization in the field comprising one or more of the Licensed Antigens in combination with Adjuvant as an ingredient or component in any formulation, configuration, combination and/or delivery system, in which Adjuvant induces, augments, fine-tunes or enhances the Antigen specific immune response of any of such Licensed Antigens contained within Product.

The patents relate to Nucleic Acid and lmmunostimulatory methods and processes.

Field of Use

The Field shall mean the use of Adjuvant in combination with Licensed Antigens as part of a Product and/or Combination for the purpose of inducing, augmenting, fine-tuning or enhancing in vivo, in vitro or ex vivo of an Antigen specific immune response and in all cases for Prophylactic Immunization and/or Therapeutic Immunization against Licensed Cancers in humans, excluding Specific Field.

Specific Field shall mean without limitation the use of Adjuvant in combination with DNA Vaccines or other than in combination with a Licensed Antigen and independently from a Licensed Antigen or in combination with antibodies in passive immunotherapy applications when not combined with a tumor Antigen; or in all non Antigen specific ex vivo applications or for all purposes other than eliciting, inducing, augmenting, fine-tuning or enhancing an Antigen-specific immune response.

License Grant

Pursuant to the Agreement, Licensee obtained an exclusive license under Licensor patent rights and know-how to develop, make, have made, use and sell Licensed Products in the Territory.

With this amendment the parties wish to amend the Agreement to provide for the reversion of rights to Licensor under the Licensor patent rights and know-how for Influenza vaccine, HPV vaccine and HSV vaccine.

As of the Amendment Effective Date, the license granted to Licensee, and the rights and obligations of Licensee and Licensor arising therefrom, shall no longer apply to Influenza vaccine, HPV Vaccine and HSV Vaccine, and these vaccines shall no longer be deemed to be Licensed Products under the Agreement.

Hereby amended Licensor grants to Licensee an exclusive license, even as to Licensor, under Licensor know-how and patent rights to develop, make, have made, use and sell Licensed products in the Territory with the right to grant sub licenses to Affiliates of Licensee and those persons or entities through whom Licensee, in the normal course of its business collaborates in the manufacture and sale of its products; provided however, that nothing in this Agreement shall prohibit Licensor from utilizing the Licensor know-how and/or patent rights, exclusive of Licensee know-how, to develop, make, have made, use and sell, either by itself or with one or more third parties, products for the treatment of infectious diseases: provided, further, notwithstanding the preceding proviso, that Licensor shall not have any right to develop, make, have made, use, or sell, either by itself or with one or more third parties, Treatment Vaccines.

Licensor grants an option to obtain a license under theLicensor patent rights and know-how to make, have made, use, sell, offer to sell and import Cancer Vaccines in the Territory for up to three (3) Cancer targets. Such Cancer target license shall be exclusive, even as to Licensor, for each Cancer Target so licensed, and shall be sublicenseable by Licensee pursuant to the terms applicable to Licensed Products.

License Property

This amendment includes Amended Definitions Relating to Cancer targets, and, Licensed Product means a bulk or finished AIDS Vaccine, or other vaccine for the prevention of human infectious disease if licensed hereunder, which utilizes the Technology or technology which is developed by Licensor during and as a result of the research collaboration program; and upon the exercise of an Option for a Cancer vaccine, such bulk or finished Cancer vaccine for the prevention of Cancer Indications, provided, however, that if any vaccine is also capable of being used for treatment of the same human infectious disease or Cancer indication, then such therapeutic use of such vaccine shall also be considered a Licensed Product for purposes of the license being granted by Licensor to Licensee under this Agreement; and Treatment vaccines.

Treatment vaccines means a bulk or finished vaccine.

Field of Use

The field of use is for the treatment of Human Immunodeficiency Virus (HIV-1) and/or diseases caused by infection with HIV-1 in humans;  Hepatitis Virus (HBV) and or diseases caused by infection with HBV in humans; and Cancer vaccines for the treatment, but not prevention or prevention and treatment, of Cancer Indications.

License Grant

The Canadian University grants to the Canadian Licensee an exclusive license, together with the right to grant sublicenses, in the territory for the field of use to practice the Patent Rights and otherwise use the Licensed Technology and to make, develop, use, import, offer to sell, sell, market and distribute and have made, developed, used, imported, offered to sell, sold, marketed and distributed Licensed Products.

License Property

Licensor has certain compositions and methods to elicit Thl immune response for use in vaccines.

BLP25 is a cancer vaccine being developed by Licensee containing a synthetic 25 amino acid sequence of the MUC-1 cancer mucin encapsulated in a liposomal delivery system and designed to induce an immune response to cancer cells.

Field of Use

The Field of use means any and all uses of the licensed technology in liposomal cancer vaccines.

License Grant

The Licensor, government organization of England, grants the Licensee of England a nonexclusive worldwide license to use the Intellectual Property to develop, make, or have made, use, keep, sell, offer to sell, import and export Licensed Products.

License Property

The Intellectual Property shall mean the Patents and knowhow, technical information and materials, including but not limited to cell lines, owned by the Licensor necessary or useful to develop, manufacture, have manufactured, import use, keep, sell and offer to sell the Plague Antigen and/or Vaccine.

Licensed Product shall mean a Plague Antigen, and/or a Vaccine including but not limited to a Plague Vaccine Dose, the manufacture, use, sale, keeping, importing or exporting of which would, in the absence of the license granted under this Agreement, constitute an infringement of the Patents or that uses other Intellectual Property.

Plague Antigen shall mean individually each of the F1 antigen and V antigen of Yesinnia Pestis.

Plague Vaccine Dose shall mean the quantity of Vaccine given to an individual in a single dose.

Patents are for Plague Vaccines and Vaccine Compositions.

Field of Use

The field of use for any UK Government purpose or otherwise to the extent customary pursuant to standard UK Ministry of Defense contracting procedures.

License Grant

The Licensor, government organization of England, grants the Licensee of England a nonexclusive license to use the Vaccine IP to further develop, manufacture, use, keep, import, export, supply or offer to supply, or, have a Partner manufacture, use, keep, import, export, supply or offer to supply, Plague Vaccine Doses to customers in performance of Supply Contracts.

License Property

Recombinant Yersinnia Pestis F1 and V (Plague) Protective Antigen Vaccine.

Plague Vaccine Dose shall mean a dose of recombinant protective antigen plague vaccine the manufacture, use, sale, keeping1 importing or exporting of which would, lo the absence of the license granted under this Agreement, constitute an infringement or actionable misuse of the Vaccine IP.

Patents are for Plague vacclnes and Vaccine Compositions.

Field of Use

The use in the United States is for the further development manufacture and supply of recombinant protective antigen plague vaccine doses.

The use beyond the United States is for inter alia the development of a prototype recombinant protective antigen plague vaccine and the production of trials doses thereof.

License Grant

Licensor grants to a non-exclusive, sublicensable license to Licensors Intellectual Property in the Territory solely to use and import in the Field nucleic acid sequences encoding for one or more of the Initial Antigens, and to make, have made, use, sell, offer to sell and import Licensees Product(s) in the Field containing a nucleic acid sequence encoding for one or more of the Initial Antigens.

Licensor grants a non-exclusive, sublicensable license to Licensors Intellectual Property in the Territory solely to use and import nucleic acid sequences encoding for such Additional Antigen in the Field, and to make, have made, use, sell, offer to sell and import Licensee Product(s) containing a nucleic acid sequence encoding for such Additional Antigen in the Field.

For the Licensors Applicator and/or Licensors Custom Components,  Licensor grants an exclusive, sublicenseable license under the Licensors Patent Rights and Device Custom Know-How to use, sell, offer to sell and import Licensors Applicators and Licensors Custom Components solely for use with a Licensee Product in the Field.

For the Trademark License, Licensor grants a non-exclusive, sublicensable license in the Field in the Territory to use such trademarks and/or trade names Controlled by Licensor, to the extent that such trademarks and/or trade names relate to Licensors Technology, solely in connection with the use, sale, offer to sell and/or import of Licensee Product.

License Property

Licensors Intellectual Property shall mean Licensors Patent Rights and Technology,  meaning any and all patents and patent applications in the Territory (which for the purposes of this Agreement shall be deemed to include certificates of invention and applications for certificates of invention) which are Controlled by Licensor during the Term,  relating to  administration of vaccines by means of or with the assistance of electroporation; or claim or cover Licensors Device Modifications, Licensors Information and Inventions or Joint Information and Inventions; or are divisions, continuations, continuations-in-part, reissues, renewals, extensions, supplementary protection certificates, and the like of any such patents and patent applications, and any foreign equivalents thereof.

Field of Use

The Field shall mean the Licensors Device-assisted delivery of a DNA vaccine for prophylactic and/or therapeutic use in diseases or medical conditions in animals or humans involving hyper plastic and/or hypertrophic cell growth (including oncology) or infectious disease.

A single Indication shall include the primary disease and variants or sub-divisions or sub-classifications within such primary disease.  For example, for purposes of the Agreement, breast cancer is a single Indication; treatment of and first line treatment of refractory metastatic breast cancer shall be treated as sub-classifications within the single Indication of breast cancer.  Treatment and prophylaxis of the same disease (e.g. breast cancer) shall be treated as the same Indication.